

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated transgenic somatic or embryonic stem cell having a mutant ~~endogenous~~ p27^{Kip1} gene lacking a Cdk2 phosphorylation site replacing the endogenous Kip1 locus such that there is a loss of endogenous wildtype p27^{Kip1} activity, wherein the mutant p27^{Kip1} gene encodes a mutant p27^{Kip1} polypeptide having a longer half-life in S phase than wildtype p27^{Kip1} polypeptide, ~~and wherein the mutation results in a loss of endogenous wild-type p27^{Kip1}~~.
2. (Original) The transgenic cell of claim 1, wherein the mutant p27^{Kip1} polypeptide inhibits Cdk2 *in vitro* kinase activity.
3. (Original) The transgenic cell of claim 1, wherein the mutant p27^{Kip1} polypeptide is p27^{T187A}.
4. - 5. (Canceled).
6. (Currently amended) The isolated transgenic ~~murine mouse~~ cell of claim ~~[[39]] 38~~, wherein the cell is a somatic cell, a primordial germ cell, an oocyte, egg, spermatoocyte, sperm cell, fertilized egg, zygote, or embryonic stem cell.
7. (Currently amended) The isolated transgenic ~~murine mouse~~ cell of claim 6, wherein the murine germ cell is an oocyte, primordial germ cell, fertilized egg, sperm cell or spermatoocyte.
8. - 37. (Canceled).
38. (Currently amended) An isolated ~~[[A]]~~ transgenic ~~murine mouse~~ cell having a mutant ~~endogenous~~ p27^{Kip1} gene lacking a Cdk2 phosphorylation site replacing the

endogenous Kip1 locus such that there is a loss of endogenous wildtype p27^{Kip1} activity, wherein
the mutant p27^{Kip1} gene encodes a mutant p27^{Kip1} polypeptide having a longer half-life in S
phase than wild-type p27^{Kip1} polypeptide.